# Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure

Study · id `cardio:ct-nct04385589` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04385589](<https://clinicaltrials.gov/study/NCT04385589>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04385589

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 100 participants.

## Technical summary

Registry record NCT04385589. Randomized; double masking; primary purpose treatment. Start 2020-05-01 (actual); primary completion 2020-12-15 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 100 participants (enrolled count; ClinicalTrials.gov record NCT04385589, source copy `cardio:ctgov-nct04385589-2022-02-16`, retrieved 2026-10-26)
- Started: 2020-05-01 (actual) (ClinicalTrials.gov record NCT04385589, source copy `cardio:ctgov-nct04385589-2022-02-16`, retrieved 2026-10-26)
- Primary completion: 2020-12-15 (actual) (ClinicalTrials.gov record NCT04385589, source copy `cardio:ctgov-nct04385589-2022-02-16`, retrieved 2026-10-26)
- Completion: 2020-12-20 (actual) (ClinicalTrials.gov record NCT04385589, source copy `cardio:ctgov-nct04385589-2022-02-16`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT04385589, source copy `cardio:ctgov-nct04385589-2022-02-16`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04385589-2022-02-16`, retrieved 2026-10-26)

## The registry's words

- Brief title: Dapagliflozin in Diabetic Patients (Type 2) With Decompensated Heart Failure
- Condition: Heart Failure
- Intervention (Drug): Dapagliflozin
- Intervention (Drug): insulin
- Lead sponsor: Assiut University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Heart failure (`cardio:heart-failure`)
- Registry intervention name matches this record: Dapagliflozin (`cardio:dapagliflozin`)
- Registry lists this organization as the lead sponsor: Assiut University (`cardio:org-assiut-university`)

## Provenance

Content hash: ba59aa45bbedee8302de47b4b86263feee944f9bd132bfd89b7739828df5c48d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
